Brevan Howard Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Brevan Howard Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.76M	Buy	309,065 +104,220	+51%	+$2.17M	0.05%	260
2026 Q1	$4.79M	Sell	204,845 -310,284	-60%	-$6.74M	0.04%	241
2025 Q4	$10.8M	Buy	515,129 +390,554	+314%	+$6.81M	0.12%	107
2025 Q3	$1.92M	Buy	124,575 +96,348	+341%	+$1.26M	0.01%	584
2025 Q2	$264K	Sell	28,227 -32,110	-53%	-$353K	﹤0.01%	1597
2025 Q1	$741K	Buy	60,337 +46,266	+329%	+$653K	0.01%	603
2024 Q4	$186K	Sell	14,071 -8,614	-38%	-$147K	﹤0.01%	921
2024 Q3	$437K	Buy	+22,685	New	+$469K	﹤0.01%	723

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Brevan Howard Capital Management's SNDX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 51% in Q2 2026, buying an estimated $2.17M and bringing the position to 309,065 shares worth $6.76M. The position accounts for 0.05% of the portfolio, ranked #260.

Brevan Howard Capital Management first reported a position in SNDX in Q3 2024 and has held it in 8 quarters since. The position peaked at $10.8M in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Brevan Howard Capital Management held 309,065 shares of Syndax Pharmaceuticals worth $6.76M as of Q2 2026.
Brevan Howard Capital Management bought 104,220 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.17M.
Syndax Pharmaceuticals made up 0.05% of Brevan Howard Capital Management's portfolio in Q2 2026, its #260 holding.
Brevan Howard Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Brevan Howard Capital Management's Syndax Pharmaceuticals position peaked at $10.8M in Q4 2025.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.